Chung-Pu Wu

Prof. Chung-Pu Wu

Department of Physiology and Pharmacology, Chang Gung University, 259 Wen-Hwa 1st Road, Kwei-Shan, Tao-Yuan 333, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
CYChi-Chen Yang
Chi-Chen Yang
YHYi-Chen Hsieh
Yi-Chen Hsieh
SLShiow-Ju Lee
Shiow-Ju Lee
SWSzu-Huei Wu
Szu-Huei Wu
CLChing-Len Liao
Ching-Len Liao
AYAndrew Yueh
Andrew Yueh
Dengue virus (DENV) causes disease globally, with an estimated 25 to 100 million new infections per year. At present, no effective vaccine is available, and treatment is supportive. In this study, we identified BP2109, a potent and selective small-molecule inhibitor of the DENV NS2B/NS3 protease, by a high-throughput screening assay using a recombinant protease complex consisting of the central hydrophilic portion of NS2B and the N terminus of the protease domain. BP2109 inhibited DENV (serotypes 1 to 4), but not Japanese encephalitis virus (JEV), replication and viral RNA synthesis without detectable cytotoxicity. The compound inhibited recombinant DENV-2 NS2B/NS3 protease with a 50% inhibitory concentration (IC50) of 15.43 ± 2.12 μM and reduced the reporter expression of the DENV-2 replicon with a 50% effective concentration (EC50) of 0.17 ± 0.01 μM. Sequencing analyses of several individual clones derived from BP2109-resistant DENV-2 RNAs revealed that two amino acid substitutions (R55K and E80K) are found in the region of NS2B, a cofactor of the NS2B/NS3 protease complex. The introduction of R55K and E80K double mutations into the dengue virus NS2B/NS3 protease and a dengue virus replicon construct conferred 10.3- and 73.8-fold resistance to BP2109, respectively. The E80K mutation was further determined to be the key mutation conferring dengue virus replicon resistance (61.3-fold) to BP2109, whereas the R55K mutation alone did not affect resistance to BP2109. Both the R55K and E80K mutations are located in the central hydrophilic portion of the NS2B cofactor, where extensive interactions with the NS3pro domain exist. Thus, our data provide evidence that BP2109 likely inhibits DENV by a novel mechanism.

22 May 2019 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
Chung-Pu WuChung-Pu Wu
Chung-Pu Wu
SLSabrina Lusvarghi
Sabrina Lusvarghi
JWJyun-Cheng Wang
Jyun-Cheng Wang
SHSung-Han Hsiao
Sung-Han Hsiao
YHYang-Hui Huang
Yang-Hui Huang
SASuresh V. Ambudkar
Suresh V. Ambudkar

1 February 2013 in Biochemical Pharmacology
Verified
Journal Article
Closed access
Chung-Pu WuChung-Pu Wu
Chung-Pu Wu
HSHong-May Sim
Hong-May Sim
YHYang-Hui Huang
Yang-Hui Huang
YLYen-Chen Liu
Yen-Chen Liu
SHSung-Han Hsiao
Sung-Han Hsiao
SHSheng-Chieh Hsu
Sheng-Chieh Hsu

19 May 2016 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
SHSung-Han Hsiao
Sung-Han Hsiao
YLYu-Jen Lu
Yu-Jen Lu
YLYan-Qing Li
Yan-Qing Li
YHYang-Hui Huang
Yang-Hui Huang
CHChia-Hung Hsieh
Chia-Hung Hsieh
Chung-Pu WuChung-Pu Wu
Chung-Pu Wu

10 October 2023 in Drug Resistance Updates
Verified
Journal Article
Closed access
Chung-Pu WuChung-Pu Wu
Chung-Pu Wu
SHSung-Han Hsiao
Sung-Han Hsiao
YWYu-shan Wu
Yu-shan Wu

13 January 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Chung-Pu WuChung-Pu Wu
Chung-Pu Wu
SHSung-Han Hsiao
Sung-Han Hsiao
YHYang-Hui Huang
Yang-Hui Huang
LHLang-Cheng Hung
Lang-Cheng Hung
YYYi-Jou Yu
Yi-Jou Yu
YWYu-shan Wu
Yu-shan Wu
The development of multidrug resistance (MDR) in cancer patients driven by the overexpression of ATP-binding cassette (ABC) transporter ABCB1 or ABCG2 in cancer cells presents one of the most daunting therapeutic complications for clinical scientists to resolve. Despite many novel therapeutic strategies that have been tested over the years, there is still no approved treatment for multidrug-resistant cancers to date. We have recently adopted a drug repurposing approach to identify therapeutic agents that are clinically active and at the same time, capable of reversing multidrug resistance mediated by ABCB1 and ABCG2. In the present study, we investigated the effect of sitravatinib, a novel multitargeted receptor tyrosine kinase inhibitor, on human ABCB1 and ABCG2 in multidrug-resistant cancer cell lines. We discovered that at submicromolar concentrations, sitravatinib re-sensitizes ABCB1- and ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. We found that sitravatinib blocks the drug efflux function of ABCB1 and ABCG2 in a concentration-dependent manner but does not significantly alter the protein expression of ABCB1 or ABCG2 in multidrug-resistant cancer cells. In conclusion, we reveal a potential drug repositioning treatment option for multidrug-resistant cancers by targeting ABCB1 and ABCG2 with sitravatinib and should be further investigated in future clinical trials.